INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2020

Nicotinamide (vitamin B3) supplementation improved inner retinal function in participants treated for glaucoma.

In a double-masked crossover trial, 57 glaucoma patients received oral placebo or nicotinamide (1.5 g/day for 6 weeks, then 3.0 g/day for 6 weeks) followed by crossover without washout. Saturated PhNR amplitude (Vmax) improved by 14.8% (95% CI: 2.8%, 26.9%; P = .02) on nicotinamide versus 5.2% (95% CI: -4.2%, 14.6%; P = .27) on placebo. The Vmax ratio improved by 12.6% (95% CI: 5.0%, 20.2%; P = .002) following nicotinamide compared to 3.6% (95% CI: -3.4%, 10.5%; P = .30) on placebo. Additionally, 27% of participants improved visual field mean deviation by ≥1 dB on nicotinamide with fewer deteriorating (4%) compared to placebo (P = .02).

Study type
Crossover, double-masked, randomized clinical trial
Who was studied
57 participants diagnosed and treated for glaucoma
What was measured
Change in inner retinal function determined by photopic negative response (PhNR) parameters and visual field mean deviation

THE PAPER

Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial.

Hui F, Tang J, Williams PA, McGuinness MB, Hadoux X, Casson RJ, Coote M, Trounce IA, Martin KR, van Wijngaarden P, Crowston JG. Clin Exp Ophthalmol, 2020.

PubMed 32721104 ↗DOI 10.1111/ceo.13818 ↗

Nutrients & adequacyOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.